Ob/Gyn Articles

Ob/Gyn

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Wimalawansa SJ et al. - BMD changes did not substantially differ between postmenopausal women who received the dose of nitroglycerin tested, in comparison to a placebo. Once-daily dosing with 22.5 mg of transdermal-administered nitroglycerin was not effective (compliance adjusted dose was -16 mg/day).


Exclusive Author Commentary
Sunil J. Wimalawansam, MD, PhD, MBA, 08/02/09

This single center, three-year double-blind, randomized, clinical study in 188 early postmenopausal subjects, half received 22.5 mg of transdermal nitroglycerin (average dose ~16 mg/day) plus calcium plus vitamin D, while the control group received a placebo ointment, calcium and vitamin D. The primary endpoint, the lumbar spine BMD did not differ significant; under dosing of subjects was the primary reason for this. Taken together with other studies, we believe that higher dosages would not only preserve BMD, but may also improve fracture rates. If this is proven the case, nitric oxide donors are likely to be the most cost-effective therapy for prevention and treatment of osteoporosis. Hence, new studies are warranted in this fires of research.

Today in Menopausal Medicine...keeping you current

A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09

Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address